Product Description
He aha ka BPC-157?
ʻO BPC-157, pōkole no "Body Protection Compound 157", he peptide synthetic i loaʻa mai kahi ʻāpana ʻāpana o Body Protection Compound (BPC) i loaʻa mai ka wai ʻōpū o ke kanaka. Aia ia i kahi kaulahao o 15 amino acids a ua manaʻo ʻia he regenerative. ʻIke ʻia ʻo BPC-157 no kāna mau hopena lapaʻau e pili ana i nā ʻiʻo a me nā ʻōnaehana o ke kino. e loaʻa i ka hopena maikaʻi ma ka ʻōpū o ka ʻōpū, ka ʻōnaehana musculoskeletal, a me ka ʻōnaehana pūpū waena.
No ka mea, ua hōʻike ʻia nā haʻawina e hiki i ka peptide BPC-157 ke hoʻoikaika i ka hoʻoponopono hou ʻana o ka ʻiʻo i loko o ka ʻōnaehana musculoskeletal, me nā tendons, ligaments a me nā ʻiʻo, a ua hōʻike ʻia i nā hopena maikaʻi i ka mālama ʻana i nā maʻi e like me nā ʻeha tendon Achilles, nā waimaka a me nā haʻihaʻi.BPC -157 ua hoʻohuli i ka manaʻo o nā mea pāʻani, bodybuilders, a me nā poʻe makemake i ka hoʻoikaika ʻana i ka hoʻōla a me ka hoʻōla.
Pehea e hana ai ka BPC-157?
ʻAʻole maopopo ka hana pololei o ka BPC-157 a ke hoʻomau ʻia nei ka noiʻi ʻana. ʻO nā hana i manaʻo ʻia e pili ana i ka hoʻolaha ʻana i ka angiogenesis, modulation o ka pane inflammatory, hoʻoulu ʻana i ka hana collagen, pale i ke koʻikoʻi oxidative, a me ka launa pū me nā mea ulu.BPC Ua hōʻike ʻia ka -157 e hoʻoikaika i ke kūkulu ʻana i nā kīʻaha koko hou, e kōkua ana i ka hoʻoponopono ʻana i ka ʻiʻo a hoʻomaikaʻi i ke kahe o ke koko. ka hana ʻana o ka collagen, ka mea e kōkua ai i ka hoʻoponopono ʻana i ka ʻiʻo a me ke kūpaʻa o ke kino.
Eia kekahi, hiki i ka AASraw BPC-157 ke launa pū me nā mea ulu e pili ana i ka hoʻoponopono ʻana a me ka hana hou ʻana, e hoʻolaha ana i ka hoʻonui ʻana o ka cellular proliferation, differentiation, a me ka hoʻoponopono hou ʻana o nā kiko. Pono e hoʻomaopopo pono i ka hana ʻana o BPC-157 i loko o ke kanaka a me kāna mau noi therapeutic kūpono.
He mea nui e kūʻai i ka BPC-157 mai kahi mea hoʻolako kaulana, i hiki ke hōʻoia i ka maikaʻi o ka peptide BPC-157. ʻO ka mea hana BPC-157ʻoihana a me ka mea hoʻolako AASraw hiki ke hoʻolako i ka BPC-157 me ke kūlana kiʻekiʻe no ke kākoʻo o ka R&D kūʻokoʻa. kikowaena a me ka hale hana. Inā loaʻa iā ʻoe nā pono, BPC-157 wholesale mai AASraw kahi koho maikaʻi loa.
Nā pōmaikaʻi o BPC-157
ʻO BPC-157, a i ʻole Body Protection Compound 157, he peptide i loaʻa mai kahi protein i loaʻa i loko o ka ʻōpū. Ua lilo ia i kumuhana o nā noiʻi he nui ma muli o kona mau hopena therapeutic. He mea nui e hoʻomaopopo i ka wā e hoʻohiki ʻia ana ka noiʻi mua ʻana, pono ka noiʻi hou aku, ʻoi aku ka nui o ke kanaka, no ka hoʻomaopopo piha ʻana i kona hopena a me ka hoʻohana pono ʻana. Eia kekahi mau pono kūpono o BPC-157.
①Hoʻohou a hoʻoponopono i ka ʻiʻo
Ua kaulana ʻo BPC-157 no kona hiki ke hoʻoulu i ka ho'ōla a me ka hoʻōla hou ʻana. Hiki i kēia peptide ke hoʻolalelale i ke kaʻina hana o nā tendon i hōʻeha ʻia, nā ligaments, nā ʻiʻo, a me nā iwi, e lilo ia i mea waiwai nui i ka mālama ʻana i nā ʻeha haʻuki, musculoskeletal disorders, a me nā kūlana ʻē aʻe. pili i ka poino kino.
②Nā Mea Kūʻai Kūʻē
Hōʻike ka BPC-157 i nā waiwai anti-inflammatory kupaianaha. Ma ka hōʻemi ʻana i ka ʻāʻī a me ka hoʻololi ʻana i ka pane ʻana o ka immune, hiki ke lilo i mea waiwai nui no ka mālama ʻana i nā kūlana i hōʻike ʻia e ka mumū mau loa e like me ka maʻi inflammatory bowel (IBD), arthritis, a me nā maʻi autoimmune like ʻole.
③Hoʻihoʻi hou i ka ʻōpū
Aia ka BPC-157 ma lalo o ka ʻimi ʻana no kona hiki ke hoʻihoʻi a me ka pale ʻana i ka ʻōpū o ka ʻōpū (GI). , hoʻemi i ka mumū, a me ka hoʻoikaika ʻana i ka hana pale ʻōpū.
④Neuroprotective hiki
Ua hōʻike ʻo BPC-157 i nā waiwai neuroprotective i nā haʻawina mua. Hiki iā ia ke hāʻawi i ka pale ʻana i ka pōʻino o ka lolo i hana ʻia e ka traumatic brain injury (TBI), stroke, a me nā maʻi neurodegenerative.
⑤Angiogenesis a me ka hoʻokumu ʻana i ke koko
Ua ʻike ʻia ʻo BPC-157 e hoʻoulu i ka angiogenesis, a i ʻole ke kūkulu ʻana i nā kīʻaha koko hou. Hiki i kēia hopena ke hoʻomaikaʻi i ka hoʻoponopono ʻana i ka ʻiʻo a me ka hoʻōla ʻana i ka ʻeha ma o ka hoʻoikaika ʻana i ke kahe koko i nā wahi i poino.
⑥ Nā Pōmaikaʻi ʻē aʻe
Hōʻike nā haʻawina mua e hiki i ka peptide BPC-157 ke hāʻawi i nā pono hou, me ka hoʻēmi ʻana i ka ʻeha, ka hoʻomaikaʻi ʻana i ke olakino a me ka maʻalahi, hoʻonui i ka hana immune, a me ka modulating neurotransmitters pili i ke ʻano a me ka cognition.
He mea koʻikoʻi ka ʻike ʻana he nui nā BPC-157 mea hana a me ka mea hoʻolako pūnaewele a i ʻole offline, akā naʻe, ʻaʻole hilinaʻi nā mea a pau. ka hoʻolako ʻana i ka BPC-157 e like me nā koi hana o CGMP, a pono e hana kēlā me kēia pūʻulu o nā huahana i kahi hōʻike maikaʻi ma mua o ke kūʻai ʻana.
Nā hopena ʻaoʻao o ka BPC-157
ʻO ka BPC-157 ka mea maʻamau i manaʻo ʻia he palekana a ʻae maikaʻi ʻia ke hoʻohana pono ʻia. Akā naʻe, e like me nā hana therapeutic, aia ka hiki ke loaʻa nā hopena ʻaoʻao. , e like me ka nui o nā haʻawina i mālama ʻia ma nā ʻano holoholona. Hiki ke ʻokoʻa nā pane o kēlā me kēia kanaka, a ʻo nā hopena ʻaoʻao e hiki mai ana e pili ana i nā hōʻike anecdotal a me nā noiʻi liʻiliʻi.
Hoʻohuhū kūloko
Ua hōʻike kekahi mau mea hoʻohana i ka loaʻa ʻana o ka ʻeha haʻahaʻa, ʻulaʻula, a i ʻole ka huhū ma ka wahi i hoʻopaʻa ʻia.
Nā pilikia hoʻoheheʻe
Hiki i ka BPC-157 ke hoʻoulu i ka ʻehaʻeha o ka digestive no ka manawa pōkole, e like me ka nausea, ka ʻōpū o ka ʻōpū, a i ʻole ka maʻi maʻi.
Nā Hana Hoʻoiho
ʻOiai kakaʻikahi, hiki i kekahi poʻe ke loaʻa i ka maʻi maʻi i ka BPC-157. Hiki i nā hōʻailona ke komo i ka ʻūhū, ka ʻāʻī, ka pehu, a i ʻole ka pilikia o ka hanu.
Ka pilina me nā lāʻau lapaʻau
Hiki i ka BPC-157 ke launa pū me kekahi mau lāʻau lapaʻau a i ʻole nā lāʻau lapaʻau.
E like me ka peptide a i ʻole ka therapeutic intervention, ua ʻōlelo ʻia e kūkākūkā me kahi ʻoihana olakino ma mua o ka hoʻohana ʻana i ka BPC-157. Hiki iā lākou ke hāʻawi i ke alakaʻi, loiloi i nā pilikia kūpono, a nānā i kāu holomua e hōʻoia i kona hoʻohana palekana a kūpono hoʻi. ʻO ke kumu kūpono he koʻikoʻi.AASraw e hoʻomalu pono i ka maikaʻi a ua hanaʻo ia i kahi hui o BPC-157 kiʻekiʻe kiʻekiʻe no ke kūʻai. Welcome e kūʻai i ka peptide BPC-157 inā pono.
BPC-157 VS.TB 500 VS.IGF-1 LR3
ʻO BPC-157, IGF-1 LR3 (Long arginine 3-IGF-1), a me TB500 (Thymosin Beta-4) he mau peptides i ʻike nui ʻia no kā lākou kōkua nui i ka ho'ōla, hoʻōla, a me ka hoʻoponopono ʻana i nā kiko. Loaʻa i kēlā me kēia peptide nā pōmaikaʻi a me nā hana.
| ʻakika'amino | Hana i ka Ho'ōla | Nā hopena koʻikoʻi |
| BPC-157 | Hoʻopilikia i ka ulu a me ka neʻe ʻana o nā fibroblasts, nā pūnaewele kuleana no ka hoʻoponopono ʻana o ka matrix extracellular. | Hoʻolalelale i ka ho'ōla ʻana i ka ʻeha (ʻiʻo, ligament, tendon, nerve), hoʻemi i ka mumū, hoʻemi i ka ʻeha, hoʻonui i ka ulu ʻana o ka hormone receptors, paipai i ka ulu ʻana o ka tendon fibroblast hou. |
| IGF-1 LR3 (Arginine lōʻihi 3-IGF-1) | Hoʻemi i ka nalo ʻana o ka ʻiʻo e pili ana i ka makahiki a hoʻoikaika i ka hypertrophy. | Hoʻomaʻamaʻa i ka synthesis protein, hoʻonui i ka hoʻoulu hou ʻana o ka ʻiʻo, hoʻoponopono i nā pono antioxidant a me ka ikaika ligament, hoʻonui i ka hyperplasia i nā ʻiʻo ʻiʻo. |
| TB500 (Thymosin Beta-4) | ʻO ke kuleana no ka ho'ōla ʻana o ka ʻiʻo i manaʻo ʻia i nā ʻiʻo a me ka ʻiʻo pili. | Hoʻoikaika i ka ho'ōla, ka ulu ʻana o ka cell, ka neʻe ʻana o ka cell, a me ka hoʻonui ʻana o ka cell. |
ʻAʻole pono e noʻonoʻo ʻia ka ʻike i hāʻawi ʻia ma ʻaneʻi he ʻōlelo aʻo lapaʻau. ʻO nā pōmaikaʻi a me nā hana o ka hana o IGF-1 LR3, TB500, a me BPC 157 i ʻōlelo ʻia ma luna nei ma muli o nā haʻawina preclinical a me kahi helu palena o nā hoʻokolohua lapaʻau. ʻOiai ua hōʻike kēia mau mea. hiki ke ho'ōla a me ka hana hou ʻana i kekahi mau ʻano, pono lākou e hoʻohana ma lalo o ke alakaʻi ʻana a ke kauka olakino ma muli o nā hopena ʻaoʻao, nā hopena lōʻihi ʻike ʻole, a me nā ʻano like ʻole o kēlā me kēia pane.
Hiki i ka BPC-157 ke kōkua i ke kino?
Ua loaʻa ka manaʻo o ka BPC-157 i ke kaiāulu bodybuilding ma muli o kāna mau pono kūpono no ka hoʻōla ʻana i ka ʻiʻo, ka hoʻōla ʻana i ka ʻeha, a me ke olakino hui.
Hoʻōla Muscle
Hiki i ka BPC-157 ke kōkua i ka hoʻoponopono hou ʻana i ka ʻiʻo ma o ka hoʻoikaika ʻana i ka hoʻoponopono ʻana o ka ʻiʻo a me ka hoʻohaʻahaʻa ʻana i ka mumū. hiki ke hoʻemi i ka hoʻomaha ma waena o nā kau aʻo.
Hoola Eha
ʻO ke kino, ʻoi aku ka nui o ka hāpai ʻana i ke kaumaha, hiki ke hoʻoikaika i nā ʻiʻo, nā ʻili, a me nā ligaments, e hoʻonui ai i ka hopena o ka hōʻeha. ma ka paipai ʻana i ka hoʻoponopono ʻana o ka ʻiʻo a me ka hoʻohaʻahaʻa ʻana i ka mumū.
Ola Hui
Pono nā bodybuilders i nā hui olakino no ka mea hoʻolaha lākou i ke ʻano maikaʻi, ke ʻano o ka neʻe ʻana, a me ka hana holoʻokoʻa. Loaʻa i ka BPC-157 nā ʻano anti-inflammatory a ua manaʻo ʻia he lāʻau lapaʻau no ka ʻeha a me ka mumū. ke olakino hui a me ka ho'ēmiʻana i ka pilikia.
He mea nui e hoʻomaopopo he hiki ke ʻokoʻa nā ʻike pilikino me BPC-157, a ua kaupalena ʻia ka noiʻi ʻepekema e noiʻi pono ana i kona hopena i ka bodybuilding. holomua kino.
Inā ʻoe e noʻonoʻo ana e hoʻohana i ka BPC-157 no nā kumu bodybuilding, ʻōlelo ʻia e kūkākūkā me kahi ʻoihana mālama ola i ʻike e pili ana i ka peptide therapies. o BPC-157 me nā mea ʻē aʻe o kāu hoʻoponopono kino kino.
BPC-157 Hōʻike Hōʻike-HNMR
He aha ka HNMR a He aha ka HNMR spectrum e haʻi aku iā ʻoe? ʻO H Nuclear Magnetic Resonance (NMR) spectroscopy kahi ʻenehana kemika analytical i hoʻohana ʻia i ka hoʻokele maikaʻi a me ka noiʻi no ka hoʻoholo ʻana i ka ʻike a me ka maʻemaʻe o kahi laʻana a me kona ʻano molekala. No ka laʻana, hiki i ka NMR ke hoʻokaʻawale i nā hui pū ʻia i ʻike ʻia. No nā pūhui i ʻike ʻole ʻia, hiki ke hoʻohana ʻia ka NMR e hoʻohālikelike i nā hale waihona puke spectral a i ʻole e kuhi pololei i ke ʻano kumu. Ke ʻike ʻia ke ʻano kumu, hiki ke hoʻohana ʻia ka NMR no ka hoʻoholo ʻana i ka conformation molecular i ka hopena a me ke aʻo ʻana i nā waiwai kino ma ka pae molekala e like me ka hoʻololi conformational, nā hoʻololi ʻana, ka solubility, a me ka diffusion.
Pehea e kūʻai ai i ka BPC-157 mai AASraw?
❶E hoʻokaʻaʻike mai iā mākou ma kā mākou ʻōnaehana nīnau leka uila, a i ʻole e waiho i kāu helu whatsapp iā mākou, e hoʻopili aku kā mākou mea kūʻai aku (CSR) me ʻoe i 12 mau hola.
❷E hāʻawi mai iā mākou i kāu helu a me kāu helu wahi i nīnau ʻia.
❸Na kā mākou CSR e hāʻawi iā ʻoe i ka ʻōlelo, ka manawa uku, ka helu ʻimi, nā ala hoʻouna a me ka lā i manaʻo ʻia (ETA).
❹E uku ʻia a hoʻouna ʻia nā waiwai i loko o 12 mau hola.
❺ Loaʻa nā waiwai a hāʻawi i nā manaʻo.
Mea kākau o kēia ʻatikala:
Kauka Monique Ua puka 'o Hong mai ke Kula Nui o UK Imperial College London Faculty of Medicine
Mea kākau moʻolelo puke moʻolelo ʻepekema:
1. Andrea Zemba Cilic
Nā Keʻena o Pharmacology and Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia
2. Anita Zenko Sever
Keʻena o ka Pathology, Kula Lapaʻau, Ke Kulanui o Zagreb, Zagreb, Kroasia
3. Sanja Masnec
Ke Kulanui o Ophthalmology, Halemai Halemai o Zagreb, Zagreb, Croatia
4. Vedran Cesarec
Keʻena o Pharmacology, Kauka Lapaʻau, University of Zagreb, Zagreb, Croatia
ʻAʻole ʻae kēia kauka/ ʻepekema i ke kūʻai, kūʻai ʻana, a hoʻohana paha i kēia huahana no kekahi kumu. ʻAʻohe pili a pili ʻole ʻo Aasraw, i hōʻike ʻia a i ʻole, me kēia kauka. ʻO ke kumu o ka haʻi ʻana i kēia kauka, ʻo ia ka hoʻomaikaʻi, hoʻomaikaʻi a hoʻomaikaʻi i ka hana noiʻi a me ka hoʻomohala piha i hana ʻia e nā ʻepekema e hana nei i kēia mea.
E hoʻomaopopo '
[1] Fosgerau K, Hoffmann T. Peptide therapeutics: kūlana o kēia manawa a me nā kuhikuhi e hiki mai ana.Drug Discov Today.2015;20: 122-128.
[2] Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 a me kāna kuleana i ka ho'ōla ʻana i ka ʻiʻo palupalu musculoskeletal. Cell Tissue Res.2019
[3] Amic F, Drmic D, Bilic Z, Krezic I, Zizek H, Peklic M, et al. Kaalo 'ana i ka nui venous occlusion a me duodenal lesions i loko o ka iole, a me ka lāʻau lapaʻau me ka gastric pentadecapeptide paʻa BPC 157, L-NAME a me L-arginine.World. J Gastroenterol.2018;24: 5366–5378.
[4] Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al.Toxicity by NSAIDs.Counteraction by stable gastric pentadecapeptide BPC 157.Curr Pharm Des.2013;19: 76–83.
[5] Jelovac,Nikola; Sikiric, Predrag; Rucman, Rudolf; Petek,Marijan; Marovic,Anton; Perovic, Darko; Seiwerth, Sven; Mise, Stjepan; Turkovic,Branko; Dodig, Gorana; Miklic,Pavle; Buljat,Gojko; Prkacin, Ingrid (1999). "Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats". European Journal of Pharmacology. 379 (1): 19–31.
[6] Sikiric,P; Seiwerth,S; Rucman,R; Kolenc,D; Vuletic,LB; Drmic,D; Grgic,T; Strbe,S; Zukanovic,G; Crvenkovic,D; Madzarac,G; Rukavina,I; Sucic,M; Baric,M; Starcevic,N; Krstonijevic,Z; Bencic,ML; Filipcic,I; Rokotov,DS; Vlainic, J (2016). "Brain-gut Axis a me Pentadecapeptide BPC 157: Theoretical and Practical Implications". ʻO Neuropharmacology o kēia manawa. 14 (8): 857–865.
